A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
FIRST
NCT03602859
 Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Ovary |
Dr. Diane Provencher
Nathalie Grenier
514-890-8000 poste 25165
|
A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer
OPAL
NCT03574779
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Ovary |
Dr. Diane Provencher
France Gauthier
514-890-8000 poste 30921
|
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
RAMP-201 (ENGOT-ov60)
NCT04625270
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Ovary |
Dr. Diane Provencher
Bonny Choy
514-890-8000 poste 24672
|
Multicenter, Open-label, phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FR? Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy
IMGN853-0420
NCT05456685
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Ovary |
Dr. Diane Provencher
Bonny Choy
514-890-8000 poste 24672
|
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FR?-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
GLORIOSA
NCT05445778
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Ovary |
Dr. Diane Provencher
Bonny Choy
514-890-8000 poste 24672
|
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
NRG-GY019
NCT04095364
Recruiting
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Ovary |
Dr. Diane Provencher
France Gauthier
514-890-8000 poste 30921
|
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer
MK-3475-B96 (KEYNOTE-B96, ENGOT-ov65)
NCT05116189
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Ovary |
Dr. Suzanne Fortin
Audrey Lamoureux
514-252-3400 poste 6258
|
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FR?-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
GLORIOSA
NCT05445778
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Ovary |
Dr. Lara DeGuerke
Samara Bloom
514-252-3400 poste 6244
|
Multicenter, Open-label, phase 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FR? Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy
IMGN853-0420
NCT05456685
Recruiting
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
Ovary |
Dr. Paul Bessette
Annie Bourbonnais
819-346-1110 poste 12890
|
Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FR?-high Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab
GLORIOSA
NCT05445778
Recruiting
|
CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE
HOPITAL FLEURIMONT
|
Ovary |
Dr. Paul Bessette
Annie Bourbonnais
819-346-1110 poste 12890
|
Groupe d'étude en oncologie du Québec